Drug Profile
LY 3056480
Alternative Names: LY3056480Latest Information Update: 29 Aug 2022
Price :
$50
*
At a glance
- Originator Audion Therapeutics
- Class Small molecules
- Mechanism of Action Amyloid precursor protein secretase inhibitors; Notch signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Sensorineural hearing loss
Most Recent Events
- 25 Aug 2022 Audion Therapeutics withdraws prior to enrolment a phase II VESTA trial in Sensorineural hearing loss (In adults, In the elderly) in USA (Intratympanic, Injection)(NCT05061758)
- 30 Sep 2021 Audion Therapeutics plans the phase II VESTA trial for Sensorineural hearing loss (In adults, In the elderly) in USA (Intratympanic, Injection) in September 2022 (NCT05061758)
- 28 Sep 2020 Phase I/II clinical trials ongoing in Sensorineural hearing loss (In adults, In the elderly) in Greece, Germany, United Kingdom (Intratympanic) (EudraCT2016-004544-10)